Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 191

Sort by

Sort Order Select

Journal Articles

CD19 CAR T cell therapy is an effective strategy for first CNS relapse in pediatric b ALL

Blood (2025) 146 (Supplement 1): 648.

https://doi.org/10.1182/blood-2025-648

Published: 2025

Journal Articles

Humanized CD19 chimeric antigen receptor (CAR) T-cell therapy for high-risk and post-CAR relapse of B-cell acute lymphoblastic leukemia

Blood (2025) 146 (Supplement 1): 646.

https://doi.org/10.1182/blood-2025-646

Published: 2025

Journal Articles

Clinical and molecular characterization of pure erythroid leukemias and sarcomas driven by nfia::CBFA2T3

Blood (2025) 146 (Supplement 1): 3510.

https://doi.org/10.1182/blood-2025-3510

Published: 2025

Journal Articles

Influence of air quality on clinical acuity at presentation in pediatric patients with newly diagnosed Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 2848.

https://doi.org/10.1182/blood-2025-2848

Published: 2025

Journal Articles

Etoposide can be safely removed from induction chemotherapy without impacting survival for pediatric acute myeloid leukemia – a report from the Children's oncology group study AAML1831

Jenna Rossoff, Jing Chen, Todd Alonzo, Jim Wang, Richard Aplenc, Alan Gamis, Betsy Hirsch, Gordana Raca, Soheil Meshinchi, Anders Kolb, Sarah Tasian, Jessica Pollard, Matthew Kutny, Todd Cooper

Blood (2025) 146 (Supplement 1): 877.

https://doi.org/10.1182/blood-2025-877

Published: 2025

Journal Articles

Initiation of ACE inhibitors or beta-blockers during frontline therapy for pediatric Acute Myeloid Leukemia and the impacts on cardiotoxicity incidence and survival outcomes: A target trial emulation

Blood (2025) 146 (Supplement 1): 876.

https://doi.org/10.1182/blood-2025-876

Published: 2025

Journal Articles

Central nervous system disease status significantly impacts survival in pediatric acute myeloid leukemia: A report from Children's Oncology Group study AAML1831

Zachary Graff, Todd Alonzo, Robert Gerbing, Jim Wang, Jessica Pollard, Soheil Meshinchi, Alan Gamis, Richard Aplenc, Betsy Hirsch, Gordana Raca, Todd Cooper, Matthew Kutny

Blood (2025) 146 (Supplement 1): 872.

https://doi.org/10.1182/blood-2025-872

Published: 2025

Journal Articles

Mitochondrial DNA heteroplasmy and haplogroup variation in pediatric Acute Myeloid Leukemia

Audrey Zhu, Lusha Cao, Yang Xie, Hongbo Xie, Liming Pei, Tina Glisovic-Aplenc, Kelly Getz, Yimei Li, Richard Aplenc

Blood (2025) 146 (Supplement 1): 1720.

https://doi.org/10.1182/blood-2025-1720

Published: 2025

Journal Articles

Early cardiotoxicity and survival in pediatric Acute Myeloid Leukemia: The mediating roles of relapse and salvage chemotherapy intensity

Blood (2025) 146 (Supplement 1): 5169.

https://doi.org/10.1182/blood-2025-5169

Published: 2025

Journal Articles

FLT3 (CD135) expression in pediatric AML is associated with specific disease characteristics and worse outcome in the setting of sorafenib theraphy: A report from the Children's Oncology Group AAML1031 protocol.

Andrew Menssen, Amenech Ashango, Todd Alonzo, Robert Gerbing, Maria Pardo, Fan-Chi Hsu, Loren Lott, Fangyan Dai, Todd Cooper, Jessica Pollard, Katherine Tarlock, Richard Aplenc, Soheil Meshinchi, Lisa Brodersen, Michael Loken, Chad Hudson

Blood (2025) 146 (Supplement 1): 5256.

https://doi.org/10.1182/blood-2025-5256

Published: 2025

Journal Articles

Optimization of induction chemotherapy in pediatric patients with Acute Myeloid Leukemia: Real-world evidence to support removal of etoposide from induction 1

Blood (2025) 146 (Supplement 1): 603.

https://doi.org/10.1182/blood-2025-603

Published: 2025

Journal Articles

Real-world post-relapse survival outcomes in children with Acute Myeloid Leukemia by race and ethnicity

Blood (2025) 146 (Supplement 1): 602.

https://doi.org/10.1182/blood-2025-602

Published: 2025

Journal Articles

Optimized treatment for pediatric patients with low-risk Acute Myeloid Leukemia: A report from the Children's oncology group study AAML1831

Reena Pabari, Chana Glasser, Todd Alonzo, Jim Wang, Richard Aplenc, Alan Gamis, Betsy Hirsch, Gordana Raca, Soheil Meshinchi, Kasey Leger, Kelly Getz, Anders Kolb, Jessica Pollard, Sarah Tasian, Matthew Kutny, Todd Cooper

Blood (2025) 146 (Supplement 1): 878.

https://doi.org/10.1182/blood-2025-878

Published: 2025

Journal Articles

Post-transplant maintenance with sorafenib is safe and effective in pediatric patients with har FLT3/ITD AML: A report from the Children's oncology group protocol AAML1031

Caitlin Elgarten, Todd Alonzo, Robert Gerbing, John Choi, Brian Fisher, Betsy Hirsch, Samir Kahwash, John Levine, Lisa Brodersen, Michael Loken, Susana Raimondi, Katherine Tarlock, Andrew Wood, Lillian Sung, Todd Cooper, Alan Gamis, Soheil Meshinchi, Richard Aplenc, Jessica Pollard

Blood (2025) 146 (Supplement 1): 1644.

https://doi.org/10.1182/blood-2025-1644

Published: 2025

Journal Articles

CD123-directed chimeric antigen receptor T-cell (CART123) therapy for relapsed/refractory pediatric acute myeloid leukemia

Blood (2025) 146 (Supplement 1): 1643.

https://doi.org/10.1182/blood-2025-1643

Published: 2025

Journal Articles

NUP98::NSD1 fusion is associated with poor outcomes in Acute Myeloid Leukemia regardless of co-occurring mutations and treatment regimen

Katherine Tarlock, Danielle Kirkey, Rhonda Ries, Jack H. Peplinski, Todd Alonzo, Robert Gerbing, Jim Wang, Todd Cooper, Alan Gamis, Richard Aplenc, Martina Pigazzi, Franco Locatelli, Jessica Pollard, Soheil Meshinchi

Blood (2025) 146 (Supplement 1): 1702.

https://doi.org/10.1182/blood-2025-1702

Published: 2025

Journal Articles

Diagnosis and Management of AML in Pediatric Patients: Consensus Recommendations from an International Expert Panel

Blood blood.2024027904.

https://doi.org/10.1182/blood.2024027904

Published: 2025

Includes: Supplemental data

Journal Articles

Serum-Based Proteomic Analysis of Cytokine Release Syndrome in Pediatric AML Patients Receiving CART123

Saamia Farooki, Han R Fisher, Anand S Bhagwat, Tina Glisovic-Aplenc, Lusha Cao, Regina M. Myers, Haley Newman, Caroline Diorio, Saar Gill, Richard Aplenc

Blood (2024) 144 (Supplement 1): 2946.

https://doi.org/10.1182/blood-2024-201034

Published: 2024

Journal Articles

Near Universal National Uptake of Dexrazoxane in the Real-World Setting Associated with Reduced Cardiac ICU Care Requirements in Pediatric Acute Myeloid Leukemia

Daniel J. Zheng, Gary Hettinger, Lusha Cao, Caitlin W. Elgarten, Brian T. Fisher, Cody Gathers, Yuan-Shung V. Huang, Jennifer Ko, Kasey Leger, Yimei Li, Regina M. Myers, Hari K. Narayan, Jose Ortiz, Alix E. Seif, Richard Aplenc, Kelly D. Getz

Blood (2024) 144 (Supplement 1): 116.

https://doi.org/10.1182/blood-2024-208120

Published: 2024

Journal Articles

Real-World Generalizability of Clinical Trial Cytomolecular Features By Race and Ethnicity in Pediatric Acute Myeloid Leukemia (AML)

Blood (2024) 144 (Supplement 1): 531.

https://doi.org/10.1182/blood-2024-198385

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CD19 CAR T cell therapy is an effective strategy for first CNS relapse in pediatric b ALL

Humanized CD19 chimeric antigen receptor (CAR) T-cell therapy for high-risk and post-CAR relapse of B-cell acute lymphoblastic leukemia

Clinical and molecular characterization of pure erythroid leukemias and sarcomas driven by nfia::CBFA2T3

Influence of air quality on clinical acuity at presentation in pediatric patients with newly diagnosed Acute Myeloid Leukemia

Etoposide can be safely removed from induction chemotherapy without impacting survival for pediatric acute myeloid leukemia – a report from the Children's oncology group study AAML1831

Initiation of ACE inhibitors or beta-blockers during frontline therapy for pediatric Acute Myeloid Leukemia and the impacts on cardiotoxicity incidence and survival outcomes: A target trial emulation

Central nervous system disease status significantly impacts survival in pediatric acute myeloid leukemia: A report from Children's Oncology Group study AAML1831

Mitochondrial DNA heteroplasmy and haplogroup variation in pediatric Acute Myeloid Leukemia

Early cardiotoxicity and survival in pediatric Acute Myeloid Leukemia: The mediating roles of relapse and salvage chemotherapy intensity

FLT3 (CD135) expression in pediatric AML is associated with specific disease characteristics and worse outcome in the setting of sorafenib theraphy: A report from the Children's Oncology Group AAML1031 protocol.

Optimization of induction chemotherapy in pediatric patients with Acute Myeloid Leukemia: Real-world evidence to support removal of etoposide from induction 1

Real-world post-relapse survival outcomes in children with Acute Myeloid Leukemia by race and ethnicity

Optimized treatment for pediatric patients with low-risk Acute Myeloid Leukemia: A report from the Children's oncology group study AAML1831

Post-transplant maintenance with sorafenib is safe and effective in pediatric patients with har FLT3/ITD AML: A report from the Children's oncology group protocol AAML1031

CD123-directed chimeric antigen receptor T-cell (CART123) therapy for relapsed/refractory pediatric acute myeloid leukemia

NUP98::NSD1 fusion is associated with poor outcomes in Acute Myeloid Leukemia regardless of co-occurring mutations and treatment regimen

Diagnosis and Management of AML in Pediatric Patients: Consensus Recommendations from an International Expert Panel

Serum-Based Proteomic Analysis of Cytokine Release Syndrome in Pediatric AML Patients Receiving CART123

Near Universal National Uptake of Dexrazoxane in the Real-World Setting Associated with Reduced Cardiac ICU Care Requirements in Pediatric Acute Myeloid Leukemia

Real-World Generalizability of Clinical Trial Cytomolecular Features By Race and Ethnicity in Pediatric Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only